Erlotinib/osimertinibDevelopment of resistance in advanced lung adenocarcinoma: case report

被引：0

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1781卷 / 1期

关键词：

D O I：

10.1007/s40278-019-71983-9

中图分类号：

学科分类号：

摘要：

引用

页码：160 / 160

共 50 条

[31] Erlotinib/osimertinibDevelopment of resistance to epidermal growth factor receptor-tyrosine-kinase inhibitors: case report
[J]. Reactions Weekly, 2016, 1626 (1) : 74 - 74
[32] Erlotinib/osimertinibInterstitial lung disease and development of resistance to erlotinib resulting in transformation of adenocarcinoma to squamous cell carcinoma: case report
[J]. Reactions Weekly, 2018, 1694 (1) : 193 - 193
[33] Afatinib/osimertinibDevelopment of drug resistance: case report
[J]. Reactions Weekly, 2020, 1823 (1) : 25 - 25
[34] Icotinib/osimertinibDevelopment of drug resistance: case report
[J]. Reactions Weekly, 2021, 1840 (1) : 215 - 215
[35] Gefitinib/osimertinibDevelopment of drug resistance: case report
[J]. Reactions Weekly, 2022, 1894 (1) : 162 - 162
[36] Erlotinib/gefitinibDevelopment of resistance as a transformation of lung adenocarcinoma to large cell neuroendocrine carcinoma: case report
[J]. Reactions Weekly, 2017, 1671 (1) : 185 - 185
[37] Cisplatin/docetaxel/osimertinibDevelopment of resistance in lung cancer and haematological toxicity: case report
[J]. Reactions Weekly, 2018, 1721 (1) : 83 - 83
[38] Gefitinib/osimertinibDevelopment of drug resistance: case report
[J]. Reactions Weekly, 2020, 1812 (1) : 133 - 133
[39] Gefitinib/osimertinibDevelopment of resistance in non-small cell lung cancer: case report
[J]. Reactions Weekly, 2019, 1744 (1) : 138 - 138
[40] Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: A case report
Sakhri L.
Meynet E.
Ferrer L.
Pirvu A.
Ferretti G.
Moro-Sibilot D.
[J]. Journal of Medical Case Reports, 8 (1)

← 1 2 3 4 5 →